Skip to main content
. 2022 May 16;37(1):1364–1374. doi: 10.1080/14756366.2022.2073444

Figure 2.

Figure 2.

Schematic representation of the proposed pharmacological chaperone strategy tackling TSD causative misfolded HexA, based on active-site directed sp2-iminosugars (a generic bicyclic amphiphilic structure with a hydrophobic R substituent is depicted).